PIK3CA and breast cancer: Activation of PIK3CA mutations and deletion of PTEN (PTEN is a key negative regulator of PI3K signaling) lead to resistance to trastuzumab and lapatinib in breast cancer cell lines, and low PTEN levels are associated with worse patient prognosis (20–22).